Clinical Trial Update: A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization [Phase 4]

View source ↗

Summary

A Phase 4 multicenter trial evaluating Sigmart for recurrent angina after coronary revascularization has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris

Drugs mentioned

• Sigmart

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Angina Pectoris | Phase 4 | Status: WITHDRAWN